{게시판이름} 상세보기 - 제목, 연구진/발행처, 발행인, 보고서번호, 조회수, 내용, 첨부파일 정보 제공
[2025기본-06] 충북 첨단바이오산업 현황 및 발전방향 새글핫이슈
연구진/발행처 : 허진아 발행일 : 2025.12.31. 보고서번호 : 조회수 : 78

​I. 서론 ······························································································································· 1

1. 연구 개요 ······························································································································· 3

2. 첨단바이오산업 정의 및 범위 ······························································································· 7

3. 첨단바이오산업의 주요 특징 ······························································································· 15


II. 첨단바이오산업 동향 ································································································· 25

1. 글로벌 첨단바이오산업 시장 전망 ······················································································ 27

2. 세계 주요국 정책 동향 ········································································································ 40

3. 국내외 주요 기술 및 기업 동향 ························································································· 53


Ⅲ. 국내 첨단바이오산업 정책 현황 ·············································································· 87

1. 국가 정책 방향 및 추진 전략 ····························································································· 89

2. 지역별 첨단바이오산업 육성 현황 ······················································································ 97


Ⅳ. 충북 첨단바이오산업 현황 및 여건 분석 ····························································· 113

1. 충북 첨단바이오산업 현황 ································································································ 115

2. 전국 대비 충북 첨단바이오산업 경쟁력 ··········································································· 139


Ⅴ. 충북 첨단바이오산업 발전방향 ·············································································· 153


참고문헌 ························································································································ 163


ABSTRACT ·················································································································· 164